Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men in the U.S. and many western countries. Although early diagnosis of PCa has improved significantly in recent years, there is a, need for more effective treatment strategies for patients presenting with advanced or metastatic disease. Earlier, we reported that the chloroform fraction of Rasagenthi Lehyam (cRL), an herbal preparation, is effective for the treatment of PCa (Ranga et al., 2004). In subsequent studies, we identified the most potent compound (cRL-CI: psoralidin) from the cRL fraction, which exhibited more potent anti-cancer effects in PCa cells compared to other isolated components from the cRL fraction. We found that cRL-CI inhibited cell viability and induced apoptosis in PC-3 and DU-145 cells. Additional studies of cRL-CI revealed (i) induction of G2/M arrest of cell cycle, (ii) inhibition of NFkB activation, (iii) alteration of Bcl2/Bax proteins, and (iv) activation of caspase signaling in cell culture models of PCa. In addition, in vivo xenograft assays substantiate these in vitro findings and show that cRL-CI inhibits prostate tumor growth in nude mice. Interestingly, our results demonstrate that cRL-CI, specifically targets cancer cells without causing significant toxicity to normal prostate epithelial cells. Although these results suggest cRL-CI alters molecular signaling, its effect on inhibition of pro-survival mechanisms, activation of pro-apoptotic signaling and cell cycle arrest are not well understood. Our proposed aims will not only delineate these potential mechanisms of action but will also address the pre-clinical evaluation of cRL-CI against PCa cells. Based on our preliminary studies, we hypothesize that cRL-CI will effectively suppress the growth of PCa due to its ability to inactivate NFkB and IAP signaling, induce cell cycle arrest and initiate caspase-mediated apoptosis in PCa. This hypothesis will be tested by the following specific aims using in vitro and in vivo approaches.
Aim 1. Study the mechanism(s) of NFkB inhibition in PCa by cRL-CI.
Aim 2. Elucidate the role of inhibition of apoptosis (lAPs) family proteins in cRL-CI induced apoptosis in PCa cells.
Aim 3. Investigate the molecular mechanism(s) for cRL-CI -induced cell cycle arrest in PCa cells.
Aim 4. Explore the anti-tumor activity of cRL-CI in animal models. The proposed studies will define the mechanism by which cRL-CI inhibits growth of PCa cells and may lead to the identification of mechanism-based biomarkers. Additionally, the results from the proposed studies can be exploited to develop chemotherapeutic and/or chemoprevention strategies for PCa, thus leading to clinical trials to determine the efficacy of the cRL-CI against PCa.

National Institute of Health (NIH)
National Center for Complementary & Alternative Medicine (NCCAM)
Research Project (R01)
Project #
Application #
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Hopp, Craig
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kentucky
Other Clinical Sciences
Schools of Allied Health Profes
United States
Zip Code
Damodaran, Chendil; Das, Trinath P; Papu John, A M Sashi et al. (2016) miR-301a expression: A prognostic marker for prostate cancer. Urol Oncol 34:336.e13-20
Das, Trinath P; Suman, Suman; Damodaran, Chendil (2014) Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog 53:537-47
Gulappa, Thippeswamy; Reddy, Ramadevi Subramani; Suman, Suman et al. (2013) Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett 337:177-83
(2011) Retraction. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) 4:1945
Kumar, Raj; Srinivasan, Sowmyalakshmi; Pahari, Pallab et al. (2010) Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther 9:2488-96
Srinivasan, Sowmyalakshmi; Kumar, Raj; Koduru, Srinivas et al. (2010) Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis 15:153-61
Kumar, Raj; Srinivasan, Sowmyalakshmi; Koduru, Srinivas et al. (2009) Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) 2:234-43
Pahari, Pallab; Rohr, J├╝rgen (2009) Total synthesis of psoralidin, an anticancer natural product. J Org Chem 74:2750-4